Concepedia

Ann W. Silk

AW

37

Publications

3K

Citations

26

H-Index

2009

Active since

Affiliations

Dana-Farber Cancer Institute(Current)

Rutgers, The State University of New Jersey

Rutgers Cancer Institute

Harvard University

Brigham and Women's Hospital

Ann W. Silk is an author at Dana-Farber Cancer Institute specializing in medicine, immunology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2009–2024

37

Publications

37

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy

Hasan Rehman, Ann W. Silk, Michael P. Kane et al. · Journal for ImmunoTherapy of Cancer · 2016 · 359 citations · Full text

, , +16

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

Matteo Palmeri, Janice M. Mehnert, Ann W. Silk et al. · ESMO Open · 2021 · 333 citations · Full text

Ipilimumab and radiation therapy for melanoma brain metastases

Ann W. Silk, M. Bassetti, Brady T. West et al. · Cancer Medicine · 2013 · 281 citations · Full text

Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer

Anshuman Panda, Janice M. Mehnert, Kim M. Hirshfield et al. · JNCI Journal of the National Cancer Institute · 2017 · 213 citations · Full text

Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors

Kim Margolin, Chihiro Morishima, Vamsidhar Velcheti et al. · Clinical Cancer Research · 2018 · 199 citations · Full text

Rows per page

1–5 of 37